Six Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026

Veracyte announced six studies involving its genomic tests will be presented at the ESMO Congress 2026, October 23-27 in Madrid. An oral presentation will provide the first evidence that the Decipher Prostate test predicts benefit from adding abiraterone to androgen deprivation therapy in clinically very high-risk, nonmetastatic prostate cancer. A late-breaking oral will report a within-trial economic analysis of Prosigna-guided chemotherapy decisions from the Phase III OPTIMA breast cancer trial. The remaining abstracts are posters covering bladder and prostate risk stratification across European and Asian real-world cohorts.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.